4D Molecular Therapeutics, Inc. (FDMT)

NMS – Real Time Price. Currency in USD

11.60

+0.08 (0.69%)

At close: Jun 26, 2026, 4:00 PM EDT

11.37

-0.23 (-1.98%)

After-hours: Jun 26, 2026, 6:03 PM EDT

12.06.2026

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on June 9, 2026, the compensation committee of the Company's board of directors granted seven new non-executive employees 66,900 Restricted Stock Units (RSUs).

10.06.2026

4D Molecular Therapeutics, Inc. (FDMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

05.06.2026

4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies Global Healthcare Conference 2026 Transcript

27.05.2026

4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in June.

22.05.2026

4D Molecular Therapeutics, Inc. (FDMT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

17.05.2026

4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy

4D Molecular Therapeutics NASDAQ: FDMT executives said the company is seeing strong clinical trial momentum for its lead retinal gene therapy candidate, 4D-150, as it advances through late-stage development for wet age-related macular degeneration and prepares to begin a Phase 3 trial in diabetic macular edema.

15.05.2026

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on May 12, 2026, the compensation committee of the Company's board of directors granted 14 new non-executive employees 141,100 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

Videos

No Data

There is no data to display

4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

EMERYVILLE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q1 2026 financial results, provided operational highlights and outlined expected upcoming milestones. 

17.04.2026

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on April 14, 2026, the compensation committee of the Company's board of directors granted five new non-executive employees 67,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

4D Molecular Therapeutics, Inc. (FDMT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

4D Molecular Therapeutics, Inc. (FDMT)

4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics, Inc. (FDMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies Global Healthcare Conference 2026 Transcript

4DMT to Participate in Upcoming Investor Conferences

4D Molecular Therapeutics, Inc. (FDMT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy

4DMT Announces New Employment Inducement Grants

Videos

No Data

Press releases

4DMT Announces New Employment Inducement Grants

4DMT Announces New Employment Inducement Grants

4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT Announces New Employment Inducement Grants

4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics, Inc. (FDMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies Global Healthcare Conference 2026 Transcript

4DMT to Participate in Upcoming Investor Conferences

4D Molecular Therapeutics, Inc. (FDMT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy

4DMT Announces New Employment Inducement Grants

Videos

No Data

Press releases

4DMT Announces New Employment Inducement Grants

4DMT Announces New Employment Inducement Grants

4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT Announces New Employment Inducement Grants

Search stocks

4D Molecular Therapeutics, Inc. (FDMT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

4D Molecular Therapeutics, Inc. (FDMT)

4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics, Inc. (FDMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies Global Healthcare Conference 2026 Transcript

4DMT to Participate in Upcoming Investor Conferences

4D Molecular Therapeutics, Inc. (FDMT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy

4DMT Announces New Employment Inducement Grants

Videos

No Data

Press releases

4DMT Announces New Employment Inducement Grants

4DMT Announces New Employment Inducement Grants

4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT Announces New Employment Inducement Grants

4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics, Inc. (FDMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies Global Healthcare Conference 2026 Transcript

4DMT to Participate in Upcoming Investor Conferences

4D Molecular Therapeutics, Inc. (FDMT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy

4DMT Announces New Employment Inducement Grants

Videos

No Data

Press releases

4DMT Announces New Employment Inducement Grants

4DMT Announces New Employment Inducement Grants

4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT Announces New Employment Inducement Grants